He called on the agency to approve more drugs based on what are known as "surrogate endpoints"  —   showing that a diabetes drug lowers blood sugar, for example  —   rather than forcing companies to prove that the product improves   outcomes like survival rates or lowering the chance for heart attacks. " Let’s bring the F. D. A. back to what its mission is, and its mission is to make sure that drugs can be labeled for safe use, and that they’re not snake oil," said Dr. Gulfo, the former chief executive of MELA Sciences, who wrote a book about his company’s failed efforts to get its skin cancer detection device approved. 